IPF involves recurrent alveolar epithelial injury with aberrant wound healing, myofibroblast proliferation, and excessive collagen deposition. TGF-β overproduction and impaired resolution of inflammation drive progressive pulmonary fibrosis, restrictive physiology, and eventual respiratory failure.
You already know from your prerequisite work on pulmonary fibrosis that fibrosis means pathological scarring — the replacement of functional tissue with rigid collagen. In IPF, the critical insight is that this is not primarily an inflammatory disease: it is a disease of aberrant epithelial repair. The distinction matters for treatment. Anti-inflammatory drugs like corticosteroids, which work in many lung diseases, are ineffective in IPF because inflammation is a secondary feature, not the driver. The primary event is recurrent microscopic injury to the type II alveolar epithelial cells (AT2 cells) that line the air sacs.
Under normal wound healing, injured epithelium triggers a temporary cascade: platelets and macrophages recruit fibroblasts to deposit provisional extracellular matrix, AT2 cells proliferate to resurface the injured area, and as the epithelium heals, TGF-β (transforming growth factor beta) and pro-fibrotic signals are switched off and the fibroblasts undergo apoptosis. In IPF, this resolution step fails. TGF-β remains chronically elevated and drives fibroblasts to differentiate into myofibroblasts — cells that combine the contractile properties of smooth muscle with the collagen-secreting properties of fibroblasts. Myofibroblasts are resistant to apoptosis and keep depositing collagen long after a normal wound would have resolved. The result is progressive thickening and stiffening of the alveolar walls.
The structural consequence is a restrictive physiology: the lungs become stiff and small, requiring more effort to expand. Total lung capacity and forced vital capacity (FVC) fall over time. Critically, the alveolar walls thicken and the gas exchange surface is destroyed, causing a disproportionate drop in diffusing capacity (DLCO) — the lung's ability to transfer oxygen across the membrane. Patients develop exertional hypoxia early because thickened alveolar walls impede oxygen diffusion even before resting oxygenation fails. This explains the hallmark presentation: progressively worsening dyspnea on exertion with a dry, non-productive cough, and "Velcro crackles" on auscultation as stiffened alveoli snap open.
The word "idiopathic" means the trigger for the initial AT2 injury is unknown — cigarette smoke, microaspiration of gastric contents, and inhaled dusts are suspected, but none is proven as necessary. What is known is that the disease progresses relentlessly. The two approved antifibrotic drugs (pirfenidone and nintedanib) slow the rate of FVC decline but do not halt or reverse fibrosis, reinforcing the lesson from chronic inflammation prerequisites: once fibrosis is established, the structural damage is permanent. The goal of therapy is to slow the rate of scar accumulation, not to dissolve existing scar — a key reason early diagnosis and treatment initiation are emphasized.
No topics depend on this one yet.